Evidence map›Paper›PMID 33303972›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2021

SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.

Yue Wang, Qianqian Xue, Qiang Zheng, Yan Jin, Xuxia Shen, Mu Yang, Xiaoyan Zhou, Yuan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Transcription Factor-Wide Association Studies to Identify Functional SNPs in Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  7. Article
  8. Review
  9. Observational
  10. Translational lung cancer research · 2024
    Article
  11. Article
  12. Article
  13. Proactive and reactive roles of TGF-β in cancer.Seminars in cancer biology · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yue Wang *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qianqian Xue *Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qiang ZhengDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yan JinDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xuxia ShenDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mu YangDepartment of Pathology, Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200032, China. yangmu1021@hotmail.com.
Xiaoyan ZhouDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yuan LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. whliyuan@hotmail.com.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMAD4 is an intracellular signaling mediator of the TGF-β pathway. Its mutation was commonly observed in gastrointestinal cancers, such as pancreatic cancer. The loss of SMAD4 on immunohistochemical staining is often used to suggest a pancreaticobiliary differentiation in evaluating a metastatic adenocarcinoma with unknown origin. However, the function and molecular mechanism of SMAD4 in non-small cell lung cancer (NSCLC) development are largely unknown. Thus, we studied the correlation between SMAD4 mutations and clinico-molecular features in the patients with NSCLC. We reported the frequencies and prognostic values of SMAD4 mutations in a Chinese NSCLC cohort using next-generation sequencing. The NSCLC cases from several public databases, including The Cancer Genome Atlas and others, were also used in this study to elucidate SMAD4-related molecular partners and mechanisms. Integrated bioinformatics analyses were conducted, such as analysis of Gene Ontology enrichment analysis, gene set enrichment analysis (GSEA), and survival analysis. Immunohistochemistry showed that the tissues harboring SMAD4 mutations tended to show SMAD4 deficiency or loss, while SMAD4 expression was significantly reduced at all stages of NSCLC cases. We found that reduced SMAD4 expression was more frequent in the patients with poor disease-free survival and resistance to platinum-based chemotherapy. SMAD4 mutation was an independent risk factor for the survival of NSCLC patients. The expression of SMAD4 was associated with that of SMAD2. The GSEA showed that SMAD4 might promote NSCLC progression by regulating proliferation, adhesion, and immune response. In conclusion, these data suggest that SMAD4 mutation or loss as well as reduced expression can be used to identify the NSCLC patients with poor survival and resistance to platinum-based chemotherapy. SMAD4 may be a predictive marker or therapeutic target in NSCLC. The source code and user's guide are freely available at Github: https://github.com/wangyue77-ab/smad4 .

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCohort StudiesFemaleHumansLungMaleMiddle AgedMutationPrognosisSmad4 ProteinSmad4 ProteinSMAD4 protein, human

Identifiers

PMID33303972
OpenAlexW3112837287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.